Next Article in Journal
Scorpions from Mexico: From Species Diversity to Venom Complexity
Previous Article in Journal
Does Dietary Deoxynivalenol Modulate the Acute Phase Reaction in Endotoxaemic Pigs?—Lessons from Clinical Signs, White Blood Cell Counts, and TNF-Alpha
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Toxins 2016, 8(1), 4; doi:10.3390/toxins8010004

Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins

1
Department of Rehabilitation Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea
2
Department of Rehabilitation Medicine, St. Paul’s Hospital, College of Medicine, The Catholic University of Korea,Wangsan-ro 180, Dongdaemoon-Gu, Seoul 02559, Korea
*
Authors to whom correspondence should be addressed.
Academic Editor: Michel R. Popoff
Received: 28 October 2015 / Revised: 30 November 2015 / Accepted: 15 December 2015 / Published: 24 December 2015
(This article belongs to the Section Bacterial Toxins)
View Full-Text   |   Download PDF [403 KB, uploaded 6 January 2016]   |  

Abstract

MT10107 is botulinum neurotoxin type A derived drug which utilizes the 150 kDa portion without complexing proteins and human serum albumin contents. To evaluate the efficacy and the safety of MT10107, it was compared with onabotulinumtoxinA in this double-blind, randomized controlled trial. Twenty-five healthy males received a randomly selected dose of MT10107 into the extensor digitorum brevis (EDB) muscle of one foot, and an equivalent dose of onabotulinumtoxinA (BOTOX) was injected into the contralateral EDB muscle. While efficacy of the administered substance was determined by measuring paretic effects on the EDB, the local spread of toxin effects was evaluated by the paretic effects on the nearby abductor hallucis (AH) and abductor digiti quinti (ADQ) muscles. Paretic effects were defined as the percentage of reduction of the compound muscle action potential (CMAP) amplitudes, measured at 14, 30, 90 days after the injection, compared to the baseline value. Intergroup (MT10107 and onabotulinumtoxinA) differences were not significant in the percentage reduction of the amplitudes in the EDB muscles. In this study, there was no significant difference in efficacy and safety between the two test drugs. MT10107 may be effective and safe as much as onabotulinumtoxinA to produce the desired paretic effect. View Full-Text
Keywords: botulinumtoxins; type A; efficacy; safety; clinical trial botulinumtoxins; type A; efficacy; safety; clinical trial
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Oh, H.-M.; Park, J.H.; Song, D.H.; Chung, M.E. Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins. Toxins 2016, 8, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top